Czechia· CZ-0225273
TERBINAFIN ACTAVIS
A terbinafine product, registered in Czechia by Actavis Group PTC ehf., Hafnarfjördur. The same ATC class is registered in 12 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Terbinafine is registered in 12 of 19 countries.
Countries holding a registration under ATC D01BA02 (terbinafine), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Terbinafine · ATC D01BA02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of terbinafine costs, country by country.
Normalised to the WHO defined daily dose (0.25 g), the median price runs from $1.38 in Italy to $3.55 in Switzerland — a ×2.6 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Terbinafine · price per daily dose (0.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$3.55
- IT Italy$1.38
The record
At a glance
SÚKL (Czech Republic)- Manufacturer
- Actavis Group PTC ehf., Hafnarfjördur
- Country
- Czechia (CZ)
- ATC code
- D01BA02
- ATC class
- Terbinafine
- Defined daily dose
- 0.25 g, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- August 24, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
375 interactions on record for terbinafine.
Graded by severity as the source publishes them — 16 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Terbinafine · interactions on record
375 records
- 16 severe
- 128 moderate
- 11 minor
- 202 info
Most severe, free to view
- EliglustatA16AX10severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- PexidartinibL01EX15severe
18 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under D01BA02
Terbinafine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ab0ab79e-7e81-4d4a-9d0d-6a4bd5684214 GET /v1/drugs/ab0ab79e-7e81-4d4a-9d0d-6a4bd5684214?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL NOB",
"source": "sukl",
"strength": "250MG",
"pack_size": "100",
"substance": "14148",
"cz_kod_sukl": "0225273",
"product_type": "CH",
"registration_state": "B",
"registration_number": "26/309/06-C"
}See everything about terbinafine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.